phase 3 retatrutide Diabetes Dialogue: Reduces Body Weight 28.7% in Trial Eli Lilly just announced striking

One study showed that there were 1 million new GLP-1 receptor agonists users from 2011 to 2023, most of whom had a BMI of 30 kg/m 2 or greater

Breast Cancer: A 3047% Risk Reduction Among the most clinically significant findings was a real-world cohort study presented at ASCO 2026, which reported that women with Type 2 diabetes or obesity using GLP-1 receptor agonists experienced a 30 to 47% reduction in breast cancer risk compared to non-users

Chris Serres: So I think, you know, the big drug companies saw that huge market and the potential there

Additional areas may be incorporated depending on clinical assessment and overall planning